Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study
© 2022 The Author(s)..
Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this phase 2/3 immuno-bridging study.
Methods: This was an observer-blind, randomised, phase 2/3 study in 1600 adults. In phase 2, 200 participants were randomized 3:1 to SII-NVX-CoV2373 or placebo. In phase 3, 1400 participants were randomized 3:1 to SII-NVX-CoV2373 or NVX-CoV2373 (940 safety cohort and 460 immunogenicity cohort). Two doses of study products (SII-NVX-CoV2373, NVX-CoV2373 or placebo) were given 3 weeks apart. Primary objectives were to demonstrate non-inferiority of SII-NVX-CoV2373 to NVX-CoV2373 in terms of geometric mean ELISA units (GMEU) ratio of anti-S IgG antibodies 14 days after the second dose (day 36) and to determine the incidence of causally related serious adverse events (SAEs) through 180 days after the first dose. Anti-S IgG response was assessed using an Enzyme-Linked Immunosorbent Assay (ELISA) and neutralizing antibodies (nAb) were assessed by a microneutralization assay using wild type SARS CoV-2 in participants from the immunogenicity cohort at baseline, day 22, day 36 and day 180. Cell mediated immune (CMI) response was assessed in a subset of 28 participants from immunogenicity cohort by ELISpot assay at baseline, day 36 and day 180. The total follow-up was for 6 months. Trial registration: CTRI/2021/02/031554.
Findings: Total 1596 participants (200 in Phase 2 and 1396 in Phase 3) received the first dose. SII-NVX-CoV2373 was found non-inferior to NVX-CoV2373 (anti-S IgG antibodies GMEU ratio 0.91; 95% CI: 0.79, 1.06). At day 36, there was more than 58-fold rise in anti-S IgG and nAb titers compared to baseline in both the groups. On day 180 visit, these antibody titers declined to levels slightly lower than those after the first dose (13-22 fold-rise above baseline). Incidence of unsolicited and solicited AEs was similar between the SII-NVX-CoV2373 and NVX-CoV2373 groups. No adverse event of special interest (AESI) was reported. No causally related SAE was reported.
Interpretation: SII-NVX-CoV2373 induced a non-inferior immune response compared to NVX-CoV2373 and has acceptable safety profile.
Funding: SIIPL, Indian Council of Medical Research, Novavax.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
The Lancet regional health. Southeast Asia - 10(2023) vom: 20. März, Seite 100139 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kulkarni, Prasad S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunogenicity |
|---|
| Anmerkungen: |
Date Revised 10.07.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.lansea.2022.100139 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351584218 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351584218 | ||
| 003 | DE-627 | ||
| 005 | 20231226051730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lansea.2022.100139 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351584218 | ||
| 035 | |a (NLM)36647543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kulkarni, Prasad S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Author(s). | ||
| 520 | |a Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this phase 2/3 immuno-bridging study | ||
| 520 | |a Methods: This was an observer-blind, randomised, phase 2/3 study in 1600 adults. In phase 2, 200 participants were randomized 3:1 to SII-NVX-CoV2373 or placebo. In phase 3, 1400 participants were randomized 3:1 to SII-NVX-CoV2373 or NVX-CoV2373 (940 safety cohort and 460 immunogenicity cohort). Two doses of study products (SII-NVX-CoV2373, NVX-CoV2373 or placebo) were given 3 weeks apart. Primary objectives were to demonstrate non-inferiority of SII-NVX-CoV2373 to NVX-CoV2373 in terms of geometric mean ELISA units (GMEU) ratio of anti-S IgG antibodies 14 days after the second dose (day 36) and to determine the incidence of causally related serious adverse events (SAEs) through 180 days after the first dose. Anti-S IgG response was assessed using an Enzyme-Linked Immunosorbent Assay (ELISA) and neutralizing antibodies (nAb) were assessed by a microneutralization assay using wild type SARS CoV-2 in participants from the immunogenicity cohort at baseline, day 22, day 36 and day 180. Cell mediated immune (CMI) response was assessed in a subset of 28 participants from immunogenicity cohort by ELISpot assay at baseline, day 36 and day 180. The total follow-up was for 6 months. Trial registration: CTRI/2021/02/031554 | ||
| 520 | |a Findings: Total 1596 participants (200 in Phase 2 and 1396 in Phase 3) received the first dose. SII-NVX-CoV2373 was found non-inferior to NVX-CoV2373 (anti-S IgG antibodies GMEU ratio 0.91; 95% CI: 0.79, 1.06). At day 36, there was more than 58-fold rise in anti-S IgG and nAb titers compared to baseline in both the groups. On day 180 visit, these antibody titers declined to levels slightly lower than those after the first dose (13-22 fold-rise above baseline). Incidence of unsolicited and solicited AEs was similar between the SII-NVX-CoV2373 and NVX-CoV2373 groups. No adverse event of special interest (AESI) was reported. No causally related SAE was reported | ||
| 520 | |a Interpretation: SII-NVX-CoV2373 induced a non-inferior immune response compared to NVX-CoV2373 and has acceptable safety profile | ||
| 520 | |a Funding: SIIPL, Indian Council of Medical Research, Novavax | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immunogenicity | |
| 650 | 4 | |a NVX-CoV2373 | |
| 650 | 4 | |a Non-inferiority | |
| 650 | 4 | |a SII-NVX-CoV2373 | |
| 650 | 4 | |a Safety | |
| 700 | 1 | |a Kadam, Abhijit |e verfasserin |4 aut | |
| 700 | 1 | |a Godbole, Sheela |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatt, Varsha |e verfasserin |4 aut | |
| 700 | 1 | |a Raut, Abhishek |e verfasserin |4 aut | |
| 700 | 1 | |a Kohli, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Tripathi, Santanu |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Praveen |e verfasserin |4 aut | |
| 700 | 1 | |a Ludam, Rakhi |e verfasserin |4 aut | |
| 700 | 1 | |a Prabhu, Madhav |e verfasserin |4 aut | |
| 700 | 1 | |a Bavdekar, Ashish |e verfasserin |4 aut | |
| 700 | 1 | |a Gogtay, Nithya J |e verfasserin |4 aut | |
| 700 | 1 | |a Meshram, Sushant |e verfasserin |4 aut | |
| 700 | 1 | |a Kadhiravan, Tamilarasu |e verfasserin |4 aut | |
| 700 | 1 | |a Kar, Sonali |e verfasserin |4 aut | |
| 700 | 1 | |a Narayana, D H Ashwath |e verfasserin |4 aut | |
| 700 | 1 | |a Samuel, Clarence |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Govind |e verfasserin |4 aut | |
| 700 | 1 | |a Gaidhane, Abhay |e verfasserin |4 aut | |
| 700 | 1 | |a Sathyapalan, Dipu |e verfasserin |4 aut | |
| 700 | 1 | |a Raut, Sidram |e verfasserin |4 aut | |
| 700 | 1 | |a Hadda, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Bhalla, Hira Lal |e verfasserin |4 aut | |
| 700 | 1 | |a Bhamare, Chetanraj |e verfasserin |4 aut | |
| 700 | 1 | |a Dharmadhikari, Abhijeet |e verfasserin |4 aut | |
| 700 | 1 | |a Plested, Joyce S |e verfasserin |4 aut | |
| 700 | 1 | |a Cloney-Clarke, Shane |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Mingzhu |e verfasserin |4 aut | |
| 700 | 1 | |a Pryor, Melinda |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Thakar, Madhuri |e verfasserin |4 aut | |
| 700 | 1 | |a Shete, Ashwini |e verfasserin |4 aut | |
| 700 | 1 | |a Gautam, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Nivedita |e verfasserin |4 aut | |
| 700 | 1 | |a Panda, Samiran |e verfasserin |4 aut | |
| 700 | 1 | |a Shaligram, Umesh |e verfasserin |4 aut | |
| 700 | 1 | |a Poonawalla, Cyrus S |e verfasserin |4 aut | |
| 700 | 1 | |a Bhargava, Balram |e verfasserin |4 aut | |
| 700 | 1 | |a Gunale, Bhagwat |e verfasserin |4 aut | |
| 700 | 1 | |a Kapse, Dhananjay |e verfasserin |4 aut | |
| 700 | 0 | |a COVOVAX Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Kanitkar, Shubhangi A |e investigator |4 oth | |
| 700 | 1 | |a Kakrani, Arjun L |e investigator |4 oth | |
| 700 | 1 | |a Tripathy, Srikanth P |e investigator |4 oth | |
| 700 | 1 | |a Tilak, Abhijit V |e investigator |4 oth | |
| 700 | 1 | |a Dhamne, Akshay A |e investigator |4 oth | |
| 700 | 1 | |a Mirza, Shahzad Beg |e investigator |4 oth | |
| 700 | 1 | |a Athavale, Prachi V |e investigator |4 oth | |
| 700 | 1 | |a Bhowmik, Mandakini |e investigator |4 oth | |
| 700 | 1 | |a Ratnakar, Parag J |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Subodh |e investigator |4 oth | |
| 700 | 1 | |a Deotale, Vijayshri |e investigator |4 oth | |
| 700 | 1 | |a Jain, Jyoti |e investigator |4 oth | |
| 700 | 1 | |a Kalantri, Ashwini |e investigator |4 oth | |
| 700 | 1 | |a Jain, Vineet |e investigator |4 oth | |
| 700 | 1 | |a Goyal, Nidhi |e investigator |4 oth | |
| 700 | 1 | |a Arya, Alok |e investigator |4 oth | |
| 700 | 1 | |a Rongsen-Chandola, Temsunaro |e investigator |4 oth | |
| 700 | 1 | |a Dasgupta, Shreyasi |e investigator |4 oth | |
| 700 | 1 | |a Periera, Pratibha |e investigator |4 oth | |
| 700 | 1 | |a A, Vanmathi |e investigator |4 oth | |
| 700 | 1 | |a Kawade, Anand |e investigator |4 oth | |
| 700 | 1 | |a Gondhali, Arunkumar |e investigator |4 oth | |
| 700 | 1 | |a Kudyar, Palvi |e investigator |4 oth | |
| 700 | 1 | |a Singh, Abhishek |e investigator |4 oth | |
| 700 | 1 | |a Yadav, Ravi |e investigator |4 oth | |
| 700 | 1 | |a Alexander, Alina |e investigator |4 oth | |
| 700 | 1 | |a Gunasekaran, Venugopalan |e investigator |4 oth | |
| 700 | 1 | |a Dineshbabu, Sekar |e investigator |4 oth | |
| 700 | 1 | |a Samantaray, P C |e investigator |4 oth | |
| 700 | 1 | |a Ravish, H S |e investigator |4 oth | |
| 700 | 1 | |a Kamra, Deepshikha |e investigator |4 oth | |
| 700 | 1 | |a Gaidhane, Shilpa |e investigator |4 oth | |
| 700 | 1 | |a Zahiruddin, Quazi Syed |e investigator |4 oth | |
| 700 | 1 | |a Moni, Merlin |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Anil |e investigator |4 oth | |
| 700 | 1 | |a Dravid, Ameet |e investigator |4 oth | |
| 700 | 1 | |a Mohan, Anant |e investigator |4 oth | |
| 700 | 1 | |a Suri, Tejas |e investigator |4 oth | |
| 700 | 1 | |a Patel, Tejas K |e investigator |4 oth | |
| 700 | 1 | |a Kishore, Surekha |e investigator |4 oth | |
| 700 | 1 | |a Choche, Rahul |e investigator |4 oth | |
| 700 | 1 | |a Ghatage, Deepak |e investigator |4 oth | |
| 700 | 1 | |a Salvi, Sugam |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet regional health. Southeast Asia |d 2022 |g 10(2023) vom: 20. März, Seite 100139 |w (DE-627)NLM342899503 |x 2772-3682 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g day:20 |g month:03 |g pages:100139 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lansea.2022.100139 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |b 20 |c 03 |h 100139 | ||